From: Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis
Alterations | No alterations | |
---|---|---|
Gonadotroph | 24 | 32 |
Age | 54.19 (14.1) | 54 (14.1) |
Sex | ||
F | 10 (41.7%) | 11 (34.4%) |
M | 14 (58.3%) | 21 (65.6%) |
Recurrence | ||
Yes | 15 (62.5%) | 18 (56.3%) |
No | 9 (37.5%) | 14 (43.7%) |
Grade | ||
1a | 7 (29.2%) | 11 (34.4%) |
1b | 1 (4.2%) | 1 (3.1%) |
2a | 12 (50.0%) | 16 (50%) |
2b | 4 (16.6%) | 4 (12.5%) |
Size | ||
Microadenomas | 0 (0%) | 0 (0%) |
Macroadenomas | 24 (100%) | 31 (96.9%) |
Giant Adenomas | 0 (0%) | 1 (3.1%) |
Secretion | ||
Silent | 24 (100%) | 32 (100%) |
Functioning | 0 (0%) | 0 (0%) |
Immunonegative | 2 | 9 |
Age | 52.49 (7.5) | 58.36 (11.6) |
Sex | ||
F | 1 (50%) | 3 (33.3%) |
M | 1 (50%) | 6 (66.7%) |
Recurrence | ||
Yes | 1 (50%) | 4 (44.4%) |
No | 1 (50%) | 5 (55.6%) |
Grade | ||
1a | 0 (0%) | 2 (22.2%) |
1b | 0 (0%) | 1 (11.1%) |
2a | 2 (100%) | 6 (66.7%) |
2b | 0 (0%) | 0 (0%) |
Size | ||
Microadenomas | 0 (0%) | 0 (0%) |
Macroadenomas | 2 (100%) | 8 (88.9%) |
Giant Adenomas | 0 (0%) | 1 (11.1%) |
Secretion | ||
Silent | 2 (100%) | 9 (100%) |
Functioning | 0 (0%) | 0 (0%) |
Somatotroph | 37 | 19 |
Age | 44.36 (12.9) | 41.84 (10.8) |
Sex | ||
F | 18 (48.7%) | 12 (63.2%) |
M | 19 (51.3%) | 7 (36.8%) |
Recurrence | ||
Yes | 23 (62.2%) | 17 (89.5%) |
No | 14 (37.8%) | 2 (10.5%) |
Grade | ||
1a | 12 (32.4%) | 4 (21.1%) |
1b | 2 (5.4%) | 0 (0%) |
2a | 16 (43.3%) | 10 (52.6%) |
2b | 7 (18.9%) | 5 (26.3%) |
Size | ||
Microadenomas | 3 (8.1%) | 1 (5.6%) |
Macroadenomas | 33 (89.2%) | 17 (94.4%) |
Giant Adenomas | 1 (2.7%) | 0 (0%) |
GNAS | ||
WT | 25 (67.6%) | 15 (78.9%) |
Mutation | 10 (27.0%) | 3 (15.8%) |
Not available | 2 (5.4%) | 1 (5.3%) |
Secretion | ||
Silent | 0 (0%) | 4 (21.1%) |
Functioning | 37 (100%) | 15 (78.9%) |
Lactrotroph | 34 | 5 |
Age | 42.06 (14.7) | 40.1 (6.9) |
Sex | ||
F | 11 (32.4%) | 2 (40.0%) |
M | 23 (67.6%) | 3 (60.0%) |
Recurrence | ||
Yes | 27 (79.4%) | 1 (20.0%) |
No | 7 (20.6%) | 4 (80.0%) |
Grade | ||
1a | 9 (26.5%) | 1 (20.0%) |
1b | 2 (5.9%) | 1 (20.0%) |
2a | 12 (35.3%) | 1 (20.0%) |
2b | 11 (32.3%) | 2 (40.0%) |
Size | ||
Microadenomas | 1 (2.9%) | 1 (20.0%) |
Macroadenomas | 28 (82.4%) | 4 (80.0%) |
Giant Adenomas | 5 (14.7%) | 0 (0.0%) |
Secretion | ||
Silent | 2 (5.9%) | 0 (0%) |
Functioning | 32 (94.1%) | 5 (100%) |
Corticotroph | 24 | 9 |
Age | 45.99 (12.0) | 39.37 (18.7) |
Sex | ||
F | 11 (45.8%) | 5 (55.6%) |
M | 13 (54.2%) | 4 (44.4%) |
Recurrence | ||
Yes | 13 (54.2%) | 5 (55.6%) |
No | 11 (45.8%) | 4 (44.4%) |
Grade | ||
1a | 12 (50.0%) | 4 (44.5%) |
1b | 1 (4.2%) | 0 (0.0%) |
2a | 11 (45.8%) | 3 (33.3%) |
2b | 0 (0%) | 2 (22.2%) |
Size | ||
Microadenomas | 5 (20.8%) | 2 (22.2%) |
Macroadenomas | 19 (79.2%) | 7 (77.8%) |
Giant Adenomas | 0 (0.0%) | 0 (0.0%) |
Secretion | ||
Silent | 5 (20.8%) | 3 (33.3%) |
Functioning | 19 (79.2%) | 6 (66.7%) |
USP8 | ||
WT | 17 (70.8%) | 5 (55.6%) |
Mutation | 4 (16.7%) | 1 (11.1%) |
Not available | 3 (12.5%) | 3 (33.3%) |